Rocket Pharmaceuticals (RCKT) Operating Income (2016 - 2025)
Historic Operating Income for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.2 million.
- Rocket Pharmaceuticals' Operating Income rose 2474.22% to -$52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.5 million, marking a year-over-year increase of 851.46%. This contributed to the annual value of -$273.2 million for FY2024, which is 521.68% down from last year.
- Rocket Pharmaceuticals' Operating Income amounted to -$52.2 million in Q3 2025, which was up 2474.22% from -$71.1 million recorded in Q2 2025.
- Over the past 5 years, Rocket Pharmaceuticals' Operating Income peaked at -$34.0 million during Q2 2021, and registered a low of -$73.7 million during Q2 2024.
- Its 5-year average for Operating Income is -$58.5 million, with a median of -$62.7 million in 2024.
- The largest annual percentage gain for Rocket Pharmaceuticals' Operating Income in the last 5 years was 2516.0% (2021), contrasted with its biggest fall of 8127.58% (2021).
- Over the past 5 years, Rocket Pharmaceuticals' Operating Income (Quarter) stood at -$44.3 million in 2021, then tumbled by 55.83% to -$69.1 million in 2022, then rose by 8.4% to -$63.3 million in 2023, then rose by 0.92% to -$62.7 million in 2024, then rose by 16.66% to -$52.2 million in 2025.
- Its Operating Income was -$52.2 million in Q3 2025, compared to -$71.1 million in Q2 2025 and -$64.4 million in Q1 2025.